| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
42 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-90 |
| Cash Flow (TTM) (Millions $) |
-8 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Kaleido Biosciences is a clinical-stage healthcare company focused on discovering and developing microbiome-based therapies. The company aims to harness the power of the human microbiome, which consists of trillions of microorganisms that reside in and on the human body, to treat various diseases and improve patient health.
Kaleido Biosciences utilizes its proprietary Microbiome Metabolic Therapies (MMT) platform to develop targeted, synthetic microbiome-based treatments. The MMT platform involves identifying and characterizing microbial metabolic functions and designing interventions to modulate these functions. By modifying the microbiome, Kaleido Biosciences aims to address the underlying cause of diseases instead of just treating the symptoms.
The company's pipeline includes various product candidates for the treatment of gastrointestinal diseases, metabolic diseases, and other conditions. Kaleido Biosciences is conducting clinical trials to evaluate the safety and efficacy of its therapies, with the ultimate goal of bringing these innovative treatments to patients in need.
Overall, Kaleido Biosciences is dedicated to leveraging the potential of the human microbiome to develop novel therapies that could transform the treatment of various diseases and improve patient outcomes.
Company Address: 65 Hayden Avenue Lexington 2421 MA
Company Phone Number: 674-9000 Stock Exchange / Ticker: NASDAQ KLDO
|
0.000%